ImmunoGenesis specializes in science-driven immune therapies for tumor treatment.
ImmunoGenesis has raised $5.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2025.
ImmunoGenesis's investors include Cancer Prevention and Research Institute of Texas, Cancer Focus Fund, Texas HALO Fund, Juno Capital.
ImmunoGenesis is headquartered in Houston, United States.
ImmunoGenesis specializes in science-driven immune therapies for tumor treatment.
ImmunoGenesis is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmunoGenesis — Funding & Investors." VCBacked, January 15, 2025, https://www.vcbacked.co/company/immunogenesis. Accessed August 14, 2026.
VCBacked. (2025). ImmunoGenesis — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/immunogenesis
{{cite web |title=ImmunoGenesis — Funding & Investors |url=https://www.vcbacked.co/company/immunogenesis |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated